Zydus Lifesciences gets USFDA nod for Leuprolide Acetate injection

Zydus Lifesciences Ltd on Friday said it has received final approval from the US health regulator for its generic version of Leuprolide Acetate injection used in palliative treatment of advanced prostatic cancer.

The approval by the US Food and Drug Administration (USFDA) is for Leuprolide Acetate injection of strengths 14 mg/2.8 ml (1 mg/0.2 mL) multiple-dose vial (reference listed drug Lupron Injection, 1 mg/0.2 mL), Zydus Lifesciences said in a regulatory filing.

The Leuprolide Acetate injections will be manufactured at the company’s oncology injectable manufacturing facility at SEZ1, Ahmedabad, it added.

Leuprolide Acetate injection is indicated in the palliative treatment of advanced prostatic cancer. It had annual sales of USD 69 million in the US, the company said citing IQVIA MAT September 2025 data.

Related Posts

Ministry declares PCI’s regulation on pharmacist recruitment, promotion and services as ultra vires

The ministry of health and family welfare has declared the Pharmacy Council of India’s (PCI) recently notified regulation on the pharmacist recruitment, promotion and services as ultra vires and does…

Second Documented Case of Pan-Drug Resistant Candida auris Uncovered in Kenya

NAIROBI/GENEVA— In an alarming development that underscores the accelerating global crisis of antimicrobial resistance, researchers have confirmed the detection of a rare, pan-drug resistant strain of the high-priority fungal pathogen…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Ministry declares PCI’s regulation on pharmacist recruitment, promotion and services as ultra vires

Ministry declares PCI’s regulation on pharmacist recruitment, promotion and services as ultra vires

Second Documented Case of Pan-Drug Resistant Candida auris Uncovered in Kenya

Second Documented Case of Pan-Drug Resistant Candida auris Uncovered in Kenya

AstraZeneca Pharma India opens new Mumbai corporate office, marking the next phase of growth through innovation

AstraZeneca Pharma India opens new Mumbai corporate office, marking the next phase of growth through innovation

Pharmaceuticals export reports around 4.9 per cent growth in H1 FY27

Pharmaceuticals export reports around 4.9 per cent growth in H1 FY27

NDLEA Intercepts Massive ₦6.98 Billion Tramadol Shipment Imported from India at Lagos Port

NDLEA Intercepts Massive ₦6.98 Billion Tramadol Shipment Imported from India at Lagos Port

Two More Pregnant Women In Rajasthan’s Kota Die From Kidney Complications

Two More Pregnant Women In Rajasthan’s Kota Die From Kidney Complications